INSM Stock Risk & Deep Value Analysis
Insmed Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About INSM Stock
We analyzed Insmed Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran INSM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is INSM Stock?
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
High
Regulatory Risk
Low
What Are the Red Flags for INSM?
- ⚠
Slower-than-expected commercial ramp of brensocatib due to market access challenges or physician education needs.
- ⚠
Emergence of competitive therapies or alternative treatment paradigms for NCFBE.
- ⚠
Negative readouts from ongoing clinical trials for brensocatib label expansion or pipeline assets.
Unlock INSM Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Insmed Inc (INSM) Do?
Market Cap
$37.48B
Sector
Healthcare
Industry
Biotechnology
Employees
1,271
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Visit Insmed Inc WebsiteIs INSM Stock Undervalued?
Unlock the full AI analysis for INSM
Get the complete DVR score, risk analysis, and more
Does INSM Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is primarily driven by patent protection for brensocatib and its first-in-class mechanism for NCFBE. Orphan Drug Designation further strengthens its position. Durability will depend on continued clinical differentiation against emerging treatments and successful expansion into new indications, extending its commercial lifecycle.
Moat Erosion Risks
- •Development of alternative, equally effective, or superior therapies for NCFBE (e.g., different mechanisms of action).
- •Patent expiry or successful legal challenges to brensocatib's intellectual property.
- •Failure to secure additional label expansions, limiting market potential.
INSM Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive INSM Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated early-May 2026), focusing on initial brensocatib Rx trends and commercial ramp.
- •Updates on market access and physician uptake for TRESLEVO (brensocatib).
Medium-Term (6-18 months)
- •Brensocatib label expansion trial readouts for additional inflammatory conditions (e.g., severe asthma, COPD).
- •European and Japanese regulatory approvals and commercial launches for brensocatib.
- •Pipeline updates for early-stage assets beyond brensocatib.
Long-Term (18+ months)
- •Brensocatib becoming the standard of care in NCFBE and multiple other chronic inflammatory lung diseases.
- •Successful development and commercialization of next-generation therapies in rare pulmonary diseases.
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for INSM?
- ✓
Acceleration in TRESLEVO prescription growth rates and net sales beyond initial expectations.
- ✓
Positive clinical trial data from brensocatib's label expansion programs (e.g., severe asthma, COPD).
- ✓
Consistent growth in ARIKAYCE sales and stable gross-to-net adjustments.
- ✓
Prudent capital allocation and sustained cash runway without significant dilutive financing.
Bull Case Analysis
See what could go right with Premium
Compare INSM to Similar Stocks
See how Insmed Inc stacks up against related companies in our head-to-head analysis.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for INSM (Insmed Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
